PTC Therapeutics gets the Forbes treatment
Forbes is profiling the development work underway at the "unknown" PTC Therapeutics, one of this year's Fierce 15. The feature focuses on the progress of PTC124 in mid-stage trials for Duchenne muscular dystrophy, noting that it has the potential to address a myriad of other genetic flaws as well.
- read the article on PTC Therapeutics from Forbes
Related Articlex:
Genetic therapy could cure 1,800 diseases. Report
Schering-Plough, PTC to collaborate. Report
PTC inks deal with CV. Report
Be the first to comment
More stories about Schering Plough
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
